FDA panel offers mixed view on Boston Scientific Watchman device

WASHINGTON, Oct 8 (Reuters) - An advisory panel to the U.S. Food and Drug Administration offered a mixed view of Boston Scientific Corp's Watchman heart device on Wednesday, concluding it is probably safe but not particularly effective in reducing the risk of stroke in patients with a certain type of irregular heart beat.